inhaled

Potassium iodide is used as the treatment of overactive thyroid and as protection of the thyroid gland from the influences of radiation from swallowed or inhaled radioactive iodine. It may be used after accidental exposure to radioactive iodine or before and after administration of medicine containing radioactive iodine.

GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).

Sulukast is a potent inhaled leukotriene antagonist, which was found to be effective in preventing both leukotriene_x0002_and antigen-induced bronchospasm in guinea-pigs.

Olodaterol hydrochloride (BI-1744 HCl) is a novel, long-acting β2-adrenergic agonist (EC50s: 97.7 nM for the human β2-adrenoceptor) that exerts its pharmacological effect by binding and activating β2-adrenergic receptors.

TD139 is an inhaled galectin-3 inhibitor (Kd: 14 nM).

AZD-8871 can present a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an inhaled corticosteroid [ICS]).

Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.

Cromoglicic acid , cromolyn (USAN), cromoglycate (former BAN), or cromoglicate, is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells. Because of their convenience (and perceived safety), leukotriene receptor antagonists have largely replaced it as the non-corticosteroid treatment of choice in the treatment of asthma. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.

Nezulcitinib (TD-0903) is an inhaled, lung-selective inhibitor of pan-Janus kinase (JAK) that can be used to study COVID-19-associated acute lung injury and impaired oxygenation.

Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.

AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.

PC786 shows effective antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM). PC786 is an inhaled respiratory syncytial virus L protein polymerase inhibitor.

LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.

AZD5423 is an inhaled, potent, selective, and non-steroidal modulator of glucocorticoid receptor (GR) and it effectively reduces allergen-induced responses in subjects with mild allergic asthma.

Abediterol (LAS100977) is a new potent, long-acting inhaled beta (2) -adrenergic receptor agonist being developed for the treatment of asthma and chronic obstructive pulmonary disease.

PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-0371545

Ensifentrine (Ensifentrinum) is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

Laninamivir octanoate (CS-8958) is a long acting influenza neuraminidase (NA) inhibitor which shows superior anti-influenza virus activity.

Batefenterol Succinate is a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.

Zy 15109 can be used as inhaled mast cell stabilizer.

Aztreonam lysine is an inhaled anti-pseudomonal treatment for people who have pulmonary Pseudomonas aeruginosa infection with cystic fibrosis (CF).